References
- Böttiger L E, et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; i: 1097–101
- Poller L. Oral contraceptives, blood clotting and thrombosis. Br Med Bull 1978; 34: 151–6
- Bonnar J, et al. Haemostasis and oral contraception. Contraception-fertilite-sexualite 1985; 11: 1133–7
- Ludwig H. A position paper on the relation between oral contraceptives and blood coagulation. Contraception 1979; 20: 257–61
- Fotherby K. Effect of oral contraceptives on serum lipids and cardiovascular disease. Br J Family Planning 1985; 11: 86–91
- Vessey M P. Female hormones and vascular disease. Br J Family Planning 1980, Suppl 6: 1–12
- Cullberg G, et al. Two oral contraceptives; efficacy, serum proteins and lipid metabolism. Contraception 1982; 26: 229–43
- Mall-Haefeli M. Klinische und biochemische Resultate bei der Behandlung mit Marvelon. Geburtsh Frauenheilkd 1982; 42: 215–22
- Bye P GT. Analysts of a multicentre trial of a new low-dose oral contraceptive in Great Britain. Acta Obstet Gynecol Scand 1976, Suppl 54: 61–6
- Upton V. Clinical experience with the triphasic oral contraceptive. Update on triphasic oral contraception, M Elstein. Excerpta Medica, Amsterdam 1983; 54–74
- Aznar-Ramos R, et al. Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol 1969; 105: 1144–9
- Goldzieher J W, et al. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraception. Fertil Steril 1971; 22: 609–23
- Tuimala R. Effects of the oral contraceptive combination 0.150 mg desogestrel + 0.020 mg ethinylestradiol on serum lipids, SHBG, glycosylated proteins and plasma antithrombin III activity in healthy women. Acta Obstet Gynecol Scand 1987, Suppl 144: 37–9
- Falsetti L. A new low-dose estrogen oral contraceptive combination: effects on endocrine parameters and lipid status. Contraception 1987; 36: 489–97
- Fioretti P. Clinical and metabolic study of a new pill containing 20 μg ethinylestradiol plus 0.150 mg desogestrel. Contraception 1987; 35: 229–43
- Kloosterboer H J. Effects of the oral contraceptive combination 0.150 mg desogestrel + 0.020 mg ethinylestradiol on serum lipids, including the HDL subfractions. Acta Obstet Gynecol Scand 1987, Suppl 144: 33–6
- Melis G B. Fibrinopeptide A (FPA) levels during oral contraceptive treatment. Contraception 1984; 30: 575–83